Ignite Creation Date:
2024-05-06 @ 3:03 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04500015
Status:
COMPLETED
Last Update Posted:
2021-09-29
First Post:
2020-08-02
Brief Title:
Vaginal Isonicotinic Acid Hydrazide Administration Prior to Intrauterine Device Insertion
Sponsor:
Aswan University Hospital
Organization:
Aswan University Hospital
Study Overview
Official Title:
Benefits of Self-administered Vaginal Isonicotinic Acid Hydrazide INH Administration 12 Hours Prior to Intrauterine Device Insertion in Adolescent and Young Women a Randomized Controlled Trial
Status:
COMPLETED
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate whether vaginal isonicotinic acid hydrazide administered before the levonorgestrel-releasing intrauterine system insertion reduces IUD insertion pain and difficulty in insertion in adolescents and young women
Detailed Description:
Long-acting reversible contraception methods are highly effective methods for reduction of the unplanned pregnancy rate worldwide The intrauterine device is a single procedure that provides reliable effective and long term contraception for many women However the insertion procedure can be associated with a troublesome degree of pain that prevent some women from choosing its use Different interventions have been described to decrease pain perception during intrauterine device insertion with no agreement on an effective one
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None